Gland Pharma posted a robust set of Q1 FY26 results, showcasing significant year-on-year growth across revenue, margins, and profitability.

The company’s revenue from operations stood at ₹1,505.6 crore in Q1 FY26, up 7% from ₹1,401.7 crore in Q1 FY25. This growth was supported by better product mix and operational expansion.

Gross profit rose to ₹984.5 crore, marking an 18% YoY increase compared to ₹837.5 crore last year. The gross margin improved to 65%, up from 60% a year ago.

EBITDA jumped 39% YoY to ₹367.8 crore, from ₹265.4 crore in Q1 FY25. The EBITDA margin expanded to 24%, gaining 549 basis points (bps) YoY.

Adjusted EBITDA, which includes employee stock option expenses, came in at ₹373.7 crore, up 41% YoY. The adjusted EBITDA margin improved to 25%, up 589 bps YoY.

Profit before tax (PBT) increased 43% YoY to ₹312.7 crore, up from ₹218.2 crore in the same quarter last year.

The company’s net profit (PAT) rose sharply by 50% YoY, reaching ₹215.5 crore, compared to ₹143.8 crore in Q1 FY25. The PAT margin improved to 14%, from 10% YoY—a gain of 405 bps.

Commenting on the results, Srinivas Sadu, Executive Chairman of Gland Pharma, stated, “We’re off to a positive start this year with a growth in revenue and a significant jump in profitability, which was driven by a strong performance in our base business and a turnaround at Cenexi. These results show our strategic priorities are progressing and we are strengthening our capabilities, adding new capacity, and boosting R&D with complex products and key partnerships. We’re committed to building on this strong foundation, improving our performance, and reinforcing Gland’s path toward sustainable growth